Loading stock data…
$9.30-0.07 (-0.80%)
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. in the Healthcare sector is trading at $9.30 with a market capitalization of $93M. Wall Street consensus targets $13.67 (3 analysts), implying a +46.9% move over the next 12 months. The stock is currently 51% below its 52-week high of $19.14, remaining 16.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $630,000↑ | $516,000↓ | $1.59M↓ | $3.45M↓ | $17.57M |
| Gross Profit | $439,000↑ | $392,000↓ | $1.49M↓ | $3.34M↓ | $17.02M |
| Operating Income | -$4.72M↓ | -$3.37M↓ | -$2.56M↑ | -$3.57M↓ | $3.20M |
| Net Income | -$4.83M↓ | -$4.14M↓ | -$3.41M↑ | -$4.30M↓ | $2.39M |
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy pro...